# Management of Ischemic Heart Disease With Angiwell-XR (Ranolazine)

Study · id `cardio:ct-nct03486561` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03486561](<https://clinicaltrials.gov/study/NCT03486561>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03486561

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 2000 participants.

## Technical summary

Registry record NCT03486561. Allocation not applicable; no masking; primary purpose treatment. Start 2018-04-01 (anticipated); primary completion 2018-09-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 2000 participants (planned count; ClinicalTrials.gov record NCT03486561, source copy `cardio:ctgov-nct03486561-2018-04-03`, retrieved 2026-10-31)
- Planned start: 2018-04-01 (anticipated) (ClinicalTrials.gov record NCT03486561, source copy `cardio:ctgov-nct03486561-2018-04-03`, retrieved 2026-10-31)
- Primary completion: 2018-09-30 (anticipated) (ClinicalTrials.gov record NCT03486561, source copy `cardio:ctgov-nct03486561-2018-04-03`, retrieved 2026-10-31)
- Completion: 2018-10-31 (anticipated) (ClinicalTrials.gov record NCT03486561, source copy `cardio:ctgov-nct03486561-2018-04-03`, retrieved 2026-10-31)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03486561-2018-04-03`, retrieved 2026-10-31)

## The registry's words

- Brief title: Management of Ischemic Heart Disease With Angiwell-XR (Ranolazine)
- Acronym: MIDA
- Condition: Chronic Stable Angina
- Intervention (Drug): Ranolazine
- Lead sponsor: OBS Pakistan
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Stable angina (`cardio:stable-angina`)

## Provenance

Content hash: bf3b4c8f8f08380a248ed443649a3c5c358c01c4064ce2da9233f3ba51e611a1
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
